COLLIN, R., Hansen, I., & Wang, F.-C. (May 2023). Retrospective analysis of repetitive nerve stimulation criteria in myasthenia gravis patients [Poster presentation]. ECCN 2023, Marseille, France. |
Seutin, V., WANG, F.-C., Lakaye, B., & Hansen, I. (17 December 2022). Les syndromes myasthéniques et myotoniques congénitaux: rencontre des sciences fondamentales et des sciences cliniques [Paper presentation]. Datablitz du service de neurologie du CHU de Liège, Liège, Belgium. |
Guillemin, C., Charonitis, M., Beliy, N., Requier, F., Gilsoul, J., Balteau, E., DELRUE, G., LOMMERS, E., HANSEN, I., MAQUET, P., Phillips, C., & Collette, F. (June 2022). Exploring the specificity of fatigue-related brain activity in early Multiple Sclerosis [Poster presentation]. OHBM 2022 Annual Meeting, Glasgow, United Kingdom. |
Dive, D., Dauby, S., Lommers, E., Hansen, I., Groenendyck, D., ERNON, C., & Maquet, P. (May 2022). La sclérose en plaques : une maladie neurologique dysimmunitaire inflammatoire. Revue Médicale de Liège, 77 (5-6), 384-391. |
Dauby, S., DIVE, D., LUTTERI, L., ANDRIS, C., HANSEN, I., MAQUET, P., & LOMMERS, E. (2022). Comparative study of AQP4‑NMOSD, MOGAD and seronegative NMOSD: a single‑center Belgian cohort. Acta Neurologica Belgica. doi:10.1007/s13760-021-01712-3 |
Dive, D., Dauby, S., Lommers, E., Hansen, I., & Maquet, P. (May 2020). Actualités thérapeutiques dans la sclérose en plaques. Revue Médicale de Liège, 75 (5-6), 382 - 385. |
Timmermans, G., DEPIERREUX, F., WANG, F.-C., HANSEN, I., & MAQUET, P. (16 August 2019). Cosmetic injection of botulinum toxin unmasking subclinical myasthenia gravis : a case report and literature review. Case Reports in Neurology, 11, 244-251. doi:10.1159/000502350 |
Daniel, S., LOMMERS, E., HANSEN, I., DIVE, D., GEENEN, V., Beckers, A., & VALDES SOCIN, H. G. (2019). Thyroid dysfunction after Alemtuzumab treatment for multiple sclerosis : diagnostic and therapeutic modalities. In Endocrine Abstracts - ECE 2019. |
Daniel, S., HANSEN, I., Dive, D., Geenen, V., Beckers, A., & VALDES SOCIN, H. G. (December 2018). Thyroid dysfunction after Alemtuzumab treatment for multiple sclerosis : a report of four cases. Acta Clinica Belgica, 73 (2). |
LOMMERS, E., DEPIERREUX, F., HANSEN, I., DIVE, D., & MAQUET, P. (November 2018). NMOSD with anti-MOG antibodies following anti-TNFα therapy: A case report. Multiple Sclerosis and Related Disorders, 26, 37-39. doi:10.1016/j.msard.2018.08.029 |
LOMMERS, E., DELRUE, G., REUTER, G., CALAY, P., DELVAUX, V., HANSEN, I., DIVE, D., MAQUET, P., & Phillips, C. (October 2015). Improved probabilistic segmentation of white matter lesions in multiple sclerosis [Poster presentation]. 31st congress of the European Committee for Treatment and Research in Multiple Sclerosis. |
HANSEN, I., MELON, P., CREEMERS, E., & Moonen, G. (March 2012). Structured differential diagnosis of a transient impairment of consciousness. Revue Médicale de Liège, 67 (3). |
Belachew, S., Phan-Ba, R., Bartholome, E., Delvaux, V., Hansen, I., Calay, P., El Hafsi, K., Moonen, G., Tshibanda, L., & Vokaer, M. (February 2010). Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. European Journal of Neurology, 18 (2), 240-245. doi:10.1111/j.1468-1331.2010.03112.x |
Zeevaert, B., Hansen, I., Crielaard, J.-M., & Wang, F.-C. (2002). Syndrome du canal lent associe a une translocation autosomique 2q31-9p27. Revue Neurologique, 158 (5 Pt 1), 605-8. |
Hansen, I., Petrossians, P., Thiry, A., Flandroy, P., Gaillard, R. C., Kovacs, K., Claes, F., Stevenaert, A., Piguet, P., & Beckers, A. (October 2001). Extensive inflammatory pseudotumor of the pituitary. Journal of Clinical Endocrinology and Metabolism, 86 (10), 4603-4610. doi:10.1210/jc.86.10.4603 |